Drug Profile
Metformin/voglibose - Novartis
Alternative Names: VingoseMet; Voglibose/metformin - NovartisLatest Information Update: 27 Jun 2019
Price :
$50
*
At a glance
- Originator Novartis
- Developer Athena Drug Delivery Solutions; Novartis
- Class Antihyperglycaemics; Biguanides; Inositol phosphates; Small molecules; Sugar alcohols
- Mechanism of Action Alpha-glucosidase inhibitors; AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Glucose modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diabetes mellitus
Most Recent Events
- 27 Jun 2019 Chemical structure information added
- 29 Sep 2015 Launched for Diabetes mellitus (PO) (before September 2015)